[go: up one dir, main page]

AU2003220201A1 - Purification and cloning of nmn adenylyltranserase and its therapeutic use - Google Patents

Purification and cloning of nmn adenylyltranserase and its therapeutic use

Info

Publication number
AU2003220201A1
AU2003220201A1 AU2003220201A AU2003220201A AU2003220201A1 AU 2003220201 A1 AU2003220201 A1 AU 2003220201A1 AU 2003220201 A AU2003220201 A AU 2003220201A AU 2003220201 A AU2003220201 A AU 2003220201A AU 2003220201 A1 AU2003220201 A1 AU 2003220201A1
Authority
AU
Australia
Prior art keywords
adenylyltranserase
nmn
cloning
purification
therapeutic use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003220201A
Other versions
AU2003220201A8 (en
Inventor
Hiremagalur N. Jayaram
Joel A. Yalowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Bloomington
Original Assignee
Indiana University Bloomington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Bloomington filed Critical Indiana University Bloomington
Publication of AU2003220201A1 publication Critical patent/AU2003220201A1/en
Publication of AU2003220201A8 publication Critical patent/AU2003220201A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003220201A 2002-03-26 2003-03-13 Purification and cloning of nmn adenylyltranserase and its therapeutic use Abandoned AU2003220201A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36807802P 2002-03-26 2002-03-26
US60/368,078 2002-03-26
PCT/US2003/007563 WO2003082187A2 (en) 2002-03-26 2003-03-13 Purification and cloning of nmn adenylyltranserase and its therapeutic use

Publications (2)

Publication Number Publication Date
AU2003220201A1 true AU2003220201A1 (en) 2003-10-13
AU2003220201A8 AU2003220201A8 (en) 2003-10-13

Family

ID=28675440

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003220201A Abandoned AU2003220201A1 (en) 2002-03-26 2003-03-13 Purification and cloning of nmn adenylyltranserase and its therapeutic use

Country Status (2)

Country Link
AU (1) AU2003220201A1 (en)
WO (1) WO2003082187A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009221634B2 (en) 2008-03-03 2014-05-08 Nad Life Pty Ltd Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
GB201006961D0 (en) * 2010-04-27 2010-06-09 Babraham Inst NMN modulator
EP2584041A1 (en) * 2011-10-21 2013-04-24 Industrial Cooperation Foundation Chonbuk National University Composition for preventing or treating diabetes comprising nad glycohydrolase inhibitor as active ingredient
HUE045359T2 (en) 2011-12-14 2019-12-30 Univ Texas Collateral gene inactivating biomarkers and target cells in cancer therapy
WO2013130672A2 (en) * 2012-02-27 2013-09-06 United States Of America As Represented By The Department Of Veterans Affairs Improved cancer treatments and diagnostics
WO2014019108A1 (en) * 2012-07-28 2014-02-06 深圳华大基因研究院 Nmnat1 mutant gene, primers, kit, and method for detecting same and use thereof
CN103710321B (en) * 2013-12-31 2015-04-01 邦泰生物工程(深圳)有限公司 Nicotinamide mononucleotide adenylyltransferase (Nmnat) mutant as well as coding gene and application thereof
CN107475139A (en) * 2017-09-30 2017-12-15 广州大学 A kind of pH stable types fermentation medium and its application

Also Published As

Publication number Publication date
WO2003082187A2 (en) 2003-10-09
AU2003220201A8 (en) 2003-10-13
WO2003082187A3 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
AU2002334969A1 (en) Use of stat-6 inhibitors as therapeutic agents
AU2003225669A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003225668A1 (en) Pin1-modulating compounds and methods of use thereof
EP1542720A4 (en) Treatment of tnf alpha related disorders
AU2003213673A1 (en) Pin1-modulating compounds and methods of use thereof
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
AU2001294515A1 (en) Use of stat-6 inhibitors as therapeutic agents
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
AU2003265620A1 (en) Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition
AU2003230566A1 (en) Therapeutic regulation of deoxyribonuclease-1-like-3 activity
AU2003220201A1 (en) Purification and cloning of nmn adenylyltranserase and its therapeutic use
GB0212405D0 (en) Composition and its therapeutic use
GB0211295D0 (en) Treatment of pain
GB0207410D0 (en) Compounds and their therapeutic use
AU2003228651A1 (en) Telescopic collimator and method of manufacture
AU2003219580A1 (en) Novel therapeutical use of byakangelicin
AU2003287802A1 (en) Palpometer and methods of use thereof
IL165612A0 (en) Novel arylimidazole derivatives preparation and therapeutic uses thereof
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003270615A1 (en) Treatment of steatosis using hyperthermia
AU2003250999A1 (en) Cosmetic use of lignans
AU2003240446A1 (en) Use of mob-5 in pain
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
AU2003208858A1 (en) USE OF MIP-3Alpha AND ITS RECEPTOR TO TREAT ARTHRITIS
AU2003295160A1 (en) Therapeutic use of sibutramine and analogues thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase